Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: Use relevant to Guillain-Barré syndrome

S. Usuki, K. Taguchi, Stuart A Thompson, P. B. Chapman, Robert K Yu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Campylobacteriosis is a frequent antecedent event in Guillain-Barré syndrome (GBS), inducing high-titer serum antibodies for ganglioside antigens in the peripheral nervous system (PNS). Molecular mimicry between the lipooligosaccharide (LOS) component of Campylobacter jejuni and human peripheral nerve gangliosides is believed to play an important role in the pathogenesis of GBS. Conventional treatment strategies for patients with GBS include plasmapheresis, intravenous immunoglobulin (IVIG), and immunosuppression, which are invasive or relatively ineffective. In this study, we used our animal model of GBS, in which Lewis rats were immunized with GD3-like LOS isolated from C. jejuni. The animals developed anti-GD3 ganglioside antibodies and manifested neuromuscular dysfunction. To develop novel therapeutic strategies, we treated the animals by intraperitoneal administration of an anti-GD3 antiidiotype monoclonal antibody (BEC2) that specifically interacts with the pathogenic antibody. The treated animals had a remarkable reduction of anti-GD3 antibody titers and improvement of motor nerve functions. The results suggest that ganglioside mimics, such as antiidiotype antibodies, may be powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic antiganglioside antibodies.

Original languageEnglish (US)
Pages (from-to)1651-1663
Number of pages13
JournalJournal of Neuroscience Research
Volume88
Issue number8
DOIs
StatePublished - Jun 1 2010

Fingerprint

Experimental Autoimmune Neuritis
Anti-Idiotypic Antibodies
Gangliosides
Antibodies
Campylobacter jejuni
Molecular Mimicry
Therapeutics
Plasmapheresis
Intravenous Immunoglobulins
Peripheral Nervous System
Peripheral Nerves
Immunosuppression
Animal Models
Monoclonal Antibodies
lipid-linked oligosaccharides
Antigens
Serum

Keywords

  • Anti-idiotype antibody
  • Campylobacter jejuni
  • GD3 ganglioside
  • Ganglioside
  • Guillain-Barré
  • Lipooligosaccharide
  • Syndrome

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis : Use relevant to Guillain-Barré syndrome. / Usuki, S.; Taguchi, K.; Thompson, Stuart A; Chapman, P. B.; Yu, Robert K.

In: Journal of Neuroscience Research, Vol. 88, No. 8, 01.06.2010, p. 1651-1663.

Research output: Contribution to journalArticle

@article{cddc17fa51f44d9996be57a665b7fa8a,
title = "Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: Use relevant to Guillain-Barr{\'e} syndrome",
abstract = "Campylobacteriosis is a frequent antecedent event in Guillain-Barr{\'e} syndrome (GBS), inducing high-titer serum antibodies for ganglioside antigens in the peripheral nervous system (PNS). Molecular mimicry between the lipooligosaccharide (LOS) component of Campylobacter jejuni and human peripheral nerve gangliosides is believed to play an important role in the pathogenesis of GBS. Conventional treatment strategies for patients with GBS include plasmapheresis, intravenous immunoglobulin (IVIG), and immunosuppression, which are invasive or relatively ineffective. In this study, we used our animal model of GBS, in which Lewis rats were immunized with GD3-like LOS isolated from C. jejuni. The animals developed anti-GD3 ganglioside antibodies and manifested neuromuscular dysfunction. To develop novel therapeutic strategies, we treated the animals by intraperitoneal administration of an anti-GD3 antiidiotype monoclonal antibody (BEC2) that specifically interacts with the pathogenic antibody. The treated animals had a remarkable reduction of anti-GD3 antibody titers and improvement of motor nerve functions. The results suggest that ganglioside mimics, such as antiidiotype antibodies, may be powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic antiganglioside antibodies.",
keywords = "Anti-idiotype antibody, Campylobacter jejuni, GD3 ganglioside, Ganglioside, Guillain-Barr{\'e}, Lipooligosaccharide, Syndrome",
author = "S. Usuki and K. Taguchi and Thompson, {Stuart A} and Chapman, {P. B.} and Yu, {Robert K}",
year = "2010",
month = "6",
day = "1",
doi = "10.1002/jnr.22330",
language = "English (US)",
volume = "88",
pages = "1651--1663",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis

T2 - Use relevant to Guillain-Barré syndrome

AU - Usuki, S.

AU - Taguchi, K.

AU - Thompson, Stuart A

AU - Chapman, P. B.

AU - Yu, Robert K

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Campylobacteriosis is a frequent antecedent event in Guillain-Barré syndrome (GBS), inducing high-titer serum antibodies for ganglioside antigens in the peripheral nervous system (PNS). Molecular mimicry between the lipooligosaccharide (LOS) component of Campylobacter jejuni and human peripheral nerve gangliosides is believed to play an important role in the pathogenesis of GBS. Conventional treatment strategies for patients with GBS include plasmapheresis, intravenous immunoglobulin (IVIG), and immunosuppression, which are invasive or relatively ineffective. In this study, we used our animal model of GBS, in which Lewis rats were immunized with GD3-like LOS isolated from C. jejuni. The animals developed anti-GD3 ganglioside antibodies and manifested neuromuscular dysfunction. To develop novel therapeutic strategies, we treated the animals by intraperitoneal administration of an anti-GD3 antiidiotype monoclonal antibody (BEC2) that specifically interacts with the pathogenic antibody. The treated animals had a remarkable reduction of anti-GD3 antibody titers and improvement of motor nerve functions. The results suggest that ganglioside mimics, such as antiidiotype antibodies, may be powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic antiganglioside antibodies.

AB - Campylobacteriosis is a frequent antecedent event in Guillain-Barré syndrome (GBS), inducing high-titer serum antibodies for ganglioside antigens in the peripheral nervous system (PNS). Molecular mimicry between the lipooligosaccharide (LOS) component of Campylobacter jejuni and human peripheral nerve gangliosides is believed to play an important role in the pathogenesis of GBS. Conventional treatment strategies for patients with GBS include plasmapheresis, intravenous immunoglobulin (IVIG), and immunosuppression, which are invasive or relatively ineffective. In this study, we used our animal model of GBS, in which Lewis rats were immunized with GD3-like LOS isolated from C. jejuni. The animals developed anti-GD3 ganglioside antibodies and manifested neuromuscular dysfunction. To develop novel therapeutic strategies, we treated the animals by intraperitoneal administration of an anti-GD3 antiidiotype monoclonal antibody (BEC2) that specifically interacts with the pathogenic antibody. The treated animals had a remarkable reduction of anti-GD3 antibody titers and improvement of motor nerve functions. The results suggest that ganglioside mimics, such as antiidiotype antibodies, may be powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic antiganglioside antibodies.

KW - Anti-idiotype antibody

KW - Campylobacter jejuni

KW - GD3 ganglioside

KW - Ganglioside

KW - Guillain-Barré

KW - Lipooligosaccharide

KW - Syndrome

UR - http://www.scopus.com/inward/record.url?scp=77952359297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952359297&partnerID=8YFLogxK

U2 - 10.1002/jnr.22330

DO - 10.1002/jnr.22330

M3 - Article

C2 - 20077429

AN - SCOPUS:77952359297

VL - 88

SP - 1651

EP - 1663

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 8

ER -